Lamb’s tripe extract and vitamin B12 capsules for treatment of chronic atrophic gastritis: A multicenter, randomized, double-blind, placebo parallel-controlled clinical trial

Sep 29, 2026

Upload by awa

Chronic atrophic gastritis (CAG), marked by gastric mucosal atrophy and intestinal metaplasia, is treated as a precancerous condition needing effective intervention beyond limited non–H. pylori options. This multicenter, randomized, double-blind, placebo parallel-controlled trial assessed Lamb’s tripe extract and vitamin B12 capsules (LTEVB12C) in patients with CAG without Helicobacter pylori infection. Participants aged 18–70 were histopathologically confirmed and screened for H. pylori, with prespecified inclusion and key exclusion criteria governing safety and eligibility.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages3

Reading Time8 min

AccessFree to download

Study design and participants

Eligibility and key exclusion criteria

Clinical Observation Lamb’s tripe extract and vitamin B12 capsules for treatment of chronic atrophic gastritis: A multicenter, randomized, double-blind, placebo parallel-controlled clinical trial Dongdong Xia1, Guodong Wang1, Huahong Xie1, Bo Jiang2, Hong Xu3, Zhanguo Nie4, Chengwei Tang5, Qiang Guo6, Xiaoping Zou7, Shuisheng Shi8, Tao Sun9, Shourong Shen10, Guo-Qing Li11, Xiaozhong Guo12, Xiaoyan Zhao13, Jiaming Qian14, Weixing Chen15, Aijun Liao16, Guiying Zhang17, Zhiwei Jiang18, Jielai Xia18, Jingyuan Fang19, Daiming Fan1, Kaichun Wu1 1State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, Shaanxi 710032, China; 2Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China; 3Department of Gastrointestinal Medicine, The First Hospital of Jilin University, Changchun, Jilin 130021, China; 4Department of Gastroenterology, Urumqi General Hospital of Lanzhou Military Region, Urumqi, Xinjiang 830092, China; 5Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China; 6Department of Gastroenterology, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan 650032, China; 7Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, China; 8Department of Gastroenterology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China; 9Department of Gastroenterology, Chinese PLA General Hospital, Beijing 100048, China; 10Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China; 11Department of Gastroenterology, The Second Affiliated Hospital, University of South China, Hengyang, Hunan 421001, China; 12Department of Gastroenterology, The General Hospital of the Northern Theater Command of the Chinese People’s Liberation Army, Shenyang, Liaoning 110015, China; 13Department of Gastroenterology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China; 14Department of Gastroenterology and Hepatology, Peking Union Medical College Hospital, Beijing 100730, China; 15Department of Gastroenterology, Yueyang First People’s Hospital, Yueyang, Hunan 414000, China; 16Department of Gastroenterology, The First Affiliated Hospital of South China University, Hengyang, Hunan 421001, China; 17Department of Gastroenterology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, China; 18Department of Health Statistics, Fourth Military Medical University, Xi’an, Shaanxi 710032, China; 19Division of Gastroenterology and Hepatology, NHC Key Laboratory of Digestive Diseases, State Key Laboratory for Oncogenes and Related Genes, School of Medicine, Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiao Tong University, Shanghai 200127, China. Chronic atrophic gastritis (CAG), characterized by gastric mucosal atrophy and intestinal metaplasia (IM), is a precancerous condition requiring effective intervention.[1] Although Helicobacter pylori (H. pylori) eradication is the cornerstone therapy, options for non-H. pylori CAG remains limited. Traditional Chinese herbal medicine, particularly lamb’s tripe extract and vitamin B12 capsules (LTEVB12C), have shown promise due to their bioactive components (rennet, pepsin, and mucoprotein), which enhance digestion, mucosal repair, and microbiome regulation. [2] This multicenter trial evaluated the efficacy and safety of LTEVB12C in non-H. pylori CAG. | Access this article online | | | --- | --- | | Quick Response Code: | Website:
[www.cmj.org](www.cmj.org) | | | DOI:
10.1097/CM9.0000000000003858 | Study de

FAQs

What condition does the trial target?

The trial targets chronic atrophic gastritis (CAG), characterized by gastric mucosal atrophy and intestinal metaplasia, considered a precancerous condition.

How were eligible participants selected regarding Helicobacter pylori?

Eligible patients were histopathologically confirmed CAG without H. pylori infection, initially screened using the C13/C14 breath test and confirmed by pathology.

What type of clinical study design was used?

The study was a randomized, double-blind, placebo-controlled parallel trial conducted across 16 centers in China.

Sep 29, 2026

Upload by awa